Oncolytics Biotech (ONCY) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamentally ONCY is balanced (5.1/10). Cash‑MV and inventory turnover are bullish, while Asset‑MV and income‑tax‑to‑profit are bearish. PB‑ROE ranks in group 4 with strong weight (0.29). Overall fund score 5.08 reflects modest upside but notable gaps.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value6.48

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value0.61

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.49

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value-0.09

Score2/3

Weight16.52%

1M Return5.94%

Is ONCY fundamentally strong?

ONCY scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its -893.80% ROE, 0.00% net margin, -3.60 P/E ratio, -31.27 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.